Page last updated: 2024-09-04

pomalidomide and Hematologic Malignancies

pomalidomide has been researched along with Hematologic Malignancies in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
An, Z; Chandarlapaty, S; Deng, H; Gao, H; Li, Q; Rao, Y; Su, S; Wang, J; Wu, W; Yang, H; Yang, Z; Zhu, S	1
Vij, R	1
Wiernik, PH	1
Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I	1

Reviews

2 review(s) available for pomalidomide and Hematologic Malignancies

Article	Year
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). Current treatment options in oncology, 2009, Volume: 10, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult	2009
[IMiDs in hematology]. Bulletin du cancer, 2011, Volume: 98, Issue:8 Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia	2011

Article

Year

Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).

Current treatment options in oncology, 2009, Volume: 10, Issue:1-2

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult

2009

[IMiDs in hematology].

Bulletin du cancer, 2011, Volume: 98, Issue:8

Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia

2011

Other Studies

2 other study(ies) available for pomalidomide and Hematologic Malignancies

Article	Year
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. Journal of medicinal chemistry, 2019, 08-22, Volume: 62, Issue:16 Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 6; Hematologic Neoplasms; HL-60 Cells; Humans; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Proteolysis; Pyridines; Small Molecule Libraries; Thalidomide; THP-1 Cells; Ubiquitin-Protein Ligases	2019
Haematological cancer: a step before the next leap? Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:11 Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Multiple Myeloma; Prognosis; Salvage Therapy; Thalidomide	2013

Article

Year

Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.

Journal of medicinal chemistry, 2019, 08-22, Volume: 62, Issue:16

Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 6; Hematologic Neoplasms; HL-60 Cells; Humans; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Proteolysis; Pyridines; Small Molecule Libraries; Thalidomide; THP-1 Cells; Ubiquitin-Protein Ligases

2019

Haematological cancer: a step before the next leap?

Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:11

Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Multiple Myeloma; Prognosis; Salvage Therapy; Thalidomide

2013